Challenges and future perspectives for minimal residual disease (MRD) in multiple myeloma Irene Ghobrial, MD from Dana-Farber Cancer Institute, Boston, MA, chairs a discussion on the detection of minimal residual disease (MRD) in multiple myeloma (MM) patients during the 2017 European Multiple Myeloma Academy (EMMA) in Vienna, Austria. The expert panel, featuring Hervé Avet-Loiseau, MD, […]

MM & Plasma cell dyscrasia

Benefits of alnuctamab in the treatment of R/R multiple myeloma Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, outlines the advantages of the alnuctamab (formerly CC-93269), a novel BCMAxCD3 bispecific antibody, in the treatment of patients with relapsed/refractory (R/R) disease. Dr Cerchione explains that […]

The Multiple Myeloma Research Foundation – The Future The MMRF has made precision medicine a reality for multiple myeloma patients and the entire cancer community. It’s now time to take the next leap toward a cure.

Determining Staging and Risk in Multiple Myeloma C. Ola Landgren, MD, explains important factors he uses to determine staging and risk stratification to his patient, Aurora Torres, who has multiple myeloma. View more at http://curetoday.com/ CURE: Combining science and humanity to make cancer understandable.

The recent FDA approval of teclistamab for R/R multiple myeloma In this video, Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, comments on the recent FDA approval of teclistamab, a bispecific BCMA-directed CD3 T-cell engager, for patients with relapsed/refractory (R/R) multiple myeloma. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), […]

This is Blood Cancer This is blood cancer is a programme produced by Blood Cancer UK and ITN Productions which aims to shine a light on the disease and explore how together, we’re going to improve the lives of all people affected by it. In this film, we hear from Blood Cancer UK and other […]

The importance of genomics-based stratification in multiple myeloma Monique Minnema, MD, PhD, University Medical Center Utrecht, Utrecht, Netherlands, briefly discusses the importance of genomics-based stratification in multiple myeloma and how this is applied in the clinic. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

What Patients Need To Know About Multiple Myeloma Dr. Cesar Rodriguez Valdes, Clinical Director of Multiple Myeloma, shares the symptoms of multiple myeloma, if multiple myeloma is hereditary, and information on clinical trials.

What is Leukemia? For Employees of Hospitals, Schools, Universities and Libraries: Download 8 FREE medical animations from Nucleus by signing up for a free trial: http://nmal.nucleusmedicalmedia.com/free-trial-membership-a Biology students: Subscribe to the Nucleus Biology channel to see new animations on biology and other science topics, plus short quizzes to ace your next exam: https://bit.ly/3lH1CzV You or […]